AzTrials
AzTrials

Liver CirculationNCT07337291

Double Stent for Biliary Stones in Cirrhotic Patients

A study testing Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent and Single 11.5 Fr Plastic Biliary Stent in people with Liver Circulation and Choledocholithiasis, run by National Liver Institute, Egypt at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography (ERCP). Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Liver Circulation, Choledocholithiasis, Stent
What is being tested?
Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent and Single 11.5 Fr Plastic Biliary Stent
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteEgypt
Study dates
1 Jan 2022to 1 Jan 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults with established liver cirrhosis.
  • Presence of large or complex common bile duct (CBD) stones that were non-retrievable during the initial ERCP.
  • Classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, making them unable to safely tolerate extended endoscopic procedures or surgical intervention.
  • Clinically stable and capable of undergoing the scheduled diagnostic and therapeutic procedures.
  • Provided signed informed consent before enrollment.

Who cannot join

  • Non-cirrhotic patients.
  • Patients with non-calculous causes of biliary obstruction (e.g., portal biliopathy, benign biliary strictures, or malignant biliary obstruction).
  • Acute suppurative cholangitis.
  • Contraindications to ERCP.
  • Inability to complete the scheduled 12-month follow-up time.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • National Liver Institute, Menoufia University, Egypt.

    Shibīn al Kawm, Menoufia, 32511

Other trials in Egypt

About this study

Official title: Double Versus Single Plastic Stents for Non-Retrievable Biliary Stones in Cirrhotic Patients

This prospective, single-center, interventional study enrolled 400 cirrhotic patients with large or complex common bile duct (CBD) stones that could not be removed during an initial Endoscopic Retrograde Cholangiopancreatography (ERCP). The study compared four different plastic biliary stenting strategies (single 10 Fr, double 10 Fr, single 11.5 Fr, and single 10 Fr pigtail stents) to determine the optimal approach for facilitating successful stone clearance in a subsequent ERCP and minimizing complications in this high-risk patient population.

Read the detailed description

Background and Rationale: The primary treatment for choledocholithiasis is Endoscopic Retrograde Cholangiopancreatography (ERCP) with sphincterotomy. However, complete stone clearance fails in 10-15% of cases involving complex choledochal stones (e.g., larger than 15 mm and/or more than 3 stones), often necessitating recurrent ERCP procedures. This challenge is compounded in high-risk patients, such as the elderly or those with substantial comorbidities, who cannot tolerate prolonged procedures. Failure to extract stones can also be attributed to anatomical factors like complex stones, periampullary diverticula, or ductal anomalies. While alternative methods like ESWL or lithotripsy exist, they are not universally available. Temporary plastic biliary stent placement is a safe and effective alternative, providing biliary drainage and acting as a bridge to subsequent stone removal. Short-term stenting can reduce stone size and improve the success rate of later extraction.

The aim of this work is to evaluate the role and efficiency of different types or different numbers of plastic stent application in the treatment of non-retrievable large biliary stones in liver cirrhosis.

Study Design and Setting: This is a prospective, single-center, interventional study conducted at the National Liver Institute, Menoufia University, Egypt, between January 2022 and January 2025. The study was authorized by the Institutional Ethics Committee (Approval No.: 00787/2025). A total of 400 cirrhotic patients with calculous biliary obstruction were included. Study Population and Eligibility: Participants were adults with established liver cirrhosis classified as high-risk due to moderate to severe liver disease and/or substantial comorbidities, who could not safely tolerate extended endoscopic or surgical intervention. They all presented with large or complex Common Bile Duct (CBD) stones that could not be removed during the initial ERCP. All enrolled subjects were clinically stable and provided signed informed consent. Exclusion criteria included non-cirrhotic patients, non-calculous causes of biliary obstruction (e.g., portal biliopathy, malignant obstruction), acute suppurative cholangitis, ERCP contraindications, or inability to complete the scheduled 12-month follow-up.

Interventions and Study Groups: Enrolled individuals were allocated into four parallel groups based on the type and size of the plastic biliary stent used during ERCP: Group 1 (Single plastic stent, 10 cm × 10 Fr), Group 2 (Double plastic stents, each 10 cm × 10 Fr), Group 3 (Single plastic stent, 10 cm × 11.5 Fr), and Group 4 (Single pigtail stent, 10 cm × 10 Fr). ERCP Procedure: All ERCPs were performed by expert hepatobiliary endoscopists under general anesthesia using a standard side-viewing duodenoscope. Following selective CBD cannulation, stone extraction was attempted. When complete clearance was not achievable, the appropriate plastic stent(s) were placed over a guidewire, with or without a previous sphincterotomy. Prolonged procedures, advanced lithotripsy techniques, and chemical stone dissolution were deliberately avoided due to the high-risk nature of the study population. Data Collection and Follow-up: Thorough clinical and demographic data were systematically documented. Baseline laboratory investigations included renal function tests, CBC, CRP, pancreatic enzymes, and a full liver biochemical profile. Imaging (ultrasonography and MRCP) was used to characterize stone size, number, and biliary anatomy. Patients were observed for a minimum of 24 hours post-procedure. Follow-up assessments were scheduled at 1 month and subsequently at 3-6 month intervals or on demand. The total monitoring period was 12 months, with the final assessment completed by January 2026. Follow-up involved clinical assessment, laboratory tests, and abdominal radiographs to assess biliary drainage and stent patency. Patients with signs of stent malfunction underwent repeat ERCP.

Outcome Measures: The main outcomes were stent patency and successful stone clearance at the second ERCP. Secondary objectives included reduction in stone size, all-cause mortality throughout the follow-up period, and procedure-related complications (stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage).

Statistical Analysis: Statistical analysis will be performed using IBM SPSS Statistics (version 22). Comparisons among groups will be completed using the chi-square (χ²) test or Monte Carlo correction for categorical variables, one-way ANOVA for normally distributed continuous variables, and the Kruskal-Wallis test for non-normally distributed variables. A p-value ≤ 0.05 is considered statistically significant.

Being tested
Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent, Single 11.5 Fr Plastic Biliary Stent, Single 10 Fr Pigtail Stent
Keywords
ERCP, Biliary Stent, Double Stent, Liver Cirrhosis, Non-Retrievable Stones, High-Risk Patients
Medical subject headings
Choledocholithiasis, Liver Cirrhosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Single 10 Fr Plastic Biliary StentDevice

    Single 10 Fr, 10 cm plastic stent placed endoscopically.

  • Two 10 Fr Plastic Biliary StentDevice

    Two 10 Fr, 10 cm plastic stents placed endoscopically.

  • Single 11.5 Fr Plastic Biliary StentDevice

    Single 11.5 Fr, 10 cm plastic stent placed endoscopically.

  • Single 10 Fr Pigtail StentDevice

    Single 10 Fr, 10 cm pigtail plastic stent placed endoscopically.

Study groups in NCT07337291
Study groupRoleWhat they receive
Single 10 Fr Plastic StentExperimentalPlacement of a single 10 French (Fr), 10 cm plastic biliary stent.
Receives: Device: Single 10 Fr Plastic Biliary Stent
Double 10 Fr Plastic StentsExperimentalPlacement of two 10 French (Fr), 10 cm plastic biliary stents side-by-side.
Receives: Device: Two 10 Fr Plastic Biliary Stent
Single 11.5 Fr Plastic StentExperimentalPlacement of a single 11.5 French (Fr), 10 cm plastic biliary stent.
Receives: Device: Single 11.5 Fr Plastic Biliary Stent
Single 10 Fr Pigtail StentExperimentalPlacement of a single 10 French (Fr), 10 cm pigtail plastic biliary stent.
Receives: Device: Single 10 Fr Pigtail Stent

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stent Patency

    Time from stent placement until clinical or biochemical evidence of stent occlusion (e.g., cholangitis, elevated liver enzymes, or imaging findings).

    Measured: 6 months

  2. Successful Stone Clearance in Second ERCP

    The proportion of patients in each group achieving complete clearance of common bile duct stones during the second, planned ERCP session.

    Measured: 6 months

Secondary outcomes (3)
  1. Incidence of Procedure-Related Complications

    Incidence of adverse events, including stent migration, cholangitis, post-ERCP pancreatitis, and hemorrhage.

    Measured: From stenting until 30 days after the second ERCP.

  2. Reduction in Stone Size

    Mean reduction in the largest stone diameter, measured by cholangiography or MRCP, between initial stenting and the second ERCP.

    Measured: 6 months

  3. All-Cause Mortality

    The number of deaths from any cause during the study follow-up period

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2026
  2. Study start1 Jan 2022
  3. Primary completion1 Jan 2025
  4. Study completion1 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07337291
Sponsor's protocol ID
01282612295
Other IDs
00787
Status last verified
Dec 2025
First submitted
1 Jan 2026
Last updated
13 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Lee TH, Han JH, Kim HJ, Park SM, Park SH, Kim SJ. Is the addition of choleretic agents in multiple double-pigtail biliary stents effective for difficult common bile duct stones in elderly patients? A prospective, multicenter study. Gastrointest Endosc. 2011 Jul;74(1):96-102. doi: 10.1016/j.gie.2011.03.005. Epub 2011 Apr 30.

    PubMed 21531412
  • Horiuchi A, Nakayama Y, Kajiyama M, Kato N, Kamijima T, Graham DY, Tanaka N. Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc. 2010 Jun;71(7):1200-1203.e2. doi: 10.1016/j.gie.2009.12.055. Epub 2010 Apr 18.

    PubMed 20400079
  • Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. J Clin Gastroenterol. 2001 Feb;32(2):106-18. doi: 10.1097/00004836-200102000-00004.

    PubMed 11205644

Questions about this trial

What is this clinical trial studying?

A study testing Single 10 Fr Plastic Biliary Stent, Two 10 Fr Plastic Biliary Stent and Single 11.5 Fr Plastic Biliary Stent in people with Liver Circulation and Choledocholithiasis, run by National Liver Institute, Egypt at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stent Patency (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07337291, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in